Crucell nabs $300M in Quinvaxem contracts

Dutch biotechnology firm Crucell won $300 million in contracts for it Quinvaxem pediatric vaccine, bringing total sales of the product to $800 million and pushing shares up by 3 percent. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.